커넥티드 약물전달 디바이스 시장 : 디바이스 유형별, 약제 유형별, 최종 사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Connected Drug Delivery Devices Market was valued at USD 4.98 billion in 2025 and is projected to grow to USD 5.81 billion in 2026, with a CAGR of 18.90%, reaching USD 16.75 billion by 2032.

A clear framing of how connectivity, patient-centric design, and regulatory evolution are converging to transform drug delivery devices and clinical pathways

Connected drug delivery devices are redefining the interface between therapeutics, patients, and healthcare systems by embedding sensors, software, and connectivity into traditional delivery platforms. As clinical pathways shift toward decentralized care and value-based outcomes, devices that capture adherence, dose administration, and contextual physiologic data are becoming integral to therapeutic regimens. This transformation is powered by advances in low-power electronics, secure wireless protocols, and a maturing regulatory dialogue around software as a medical device, enabling manufacturers to move beyond standalone hardware toward integrated solutions that inform clinical decision making.

Adoption is being driven by converging pressures: clinicians seek reliable adherence data to optimize treatment, payers demand proof of value, and patients favor convenience and autonomy. As a result, product development teams are rebalancing priorities to include user experience, interoperability with electronic health records, and cybersecurity by design. In parallel, commercialization strategies increasingly emphasize partnerships with digital health platforms, remote monitoring services, and specialty pharmacies. These shifts require manufacturers and stakeholders to rethink R&D pipelines, quality systems, and post-market surveillance to manage both clinical and digital performance.

Identification of the core technological, regulatory, and economic shifts that are accelerating digital integration and redefining commercial models in drug delivery

The landscape for connected drug delivery is being reshaped by several transformative shifts that extend from component supply chains to end-user behavior. First, the integration of sensors and embedded analytics is moving devices from passive dispensers to active data sources that enable closed-loop care and adaptive dosing strategies. This technical evolution is accompanied by a cultural shift among clinicians who increasingly rely on continuous data to fine-tune therapies and to demonstrate real-world effectiveness.

Second, reimbursement and procurement models are beginning to reward outcomes rather than devices alone, encouraging developers to bundle devices with services and digital therapeutics. This economic shift prompts manufacturers to design products that generate measurable value across the patient journey. Third, regulatory frameworks are adapting to software-driven functions, accelerating pathways for connected devices while simultaneously raising expectations for cybersecurity, interoperability, and post-market surveillance. Stakeholders must therefore implement robust lifecycle management processes for software updates and real-world performance monitoring.

Finally, the end-user environment is expanding beyond hospitals into homes and ambulatory settings, requiring devices to be intuitive, safe for non-clinical users, and compatible with diverse distribution channels. Collectively, these forces favor agile development models, strategic alliances with technology providers, and a relentless focus on human-centered design to ensure clinical adoption and long-term engagement.

Examination of how the 2025 United States tariff measures are reshaping supply chains, pricing pressure, and product design choices across connected drug delivery ecosystems

The cumulative impact of the United States tariffs announced in 2025 has introduced material considerations for global supply chains, component sourcing, and pricing strategies for connected drug delivery devices. Tariffs have elevated input costs for electronic components, specialized polymers, and subassemblies that are often manufactured in tariff-affected jurisdictions, prompting manufacturers to reassess supplier footprints and to accelerate qualification of alternative vendors. As firms adapt, many are pursuing regional sourcing strategies, increasing inventory buffers, and negotiating long-term agreements to stabilize procurement costs.

These adjustments have operational effects beyond unit costs. Product development timelines can extend due to new supplier validation, while inventory management requires a higher degree of coordination between procurement, production, and distribution teams. In addition, tariff-induced cost pressure intensifies scrutiny of product architectures, encouraging designers to optimize bill-of-materials and to evaluate modular designs that allow substitution of higher-cost elements. From a strategic perspective, some companies are exploring partial onshoring of assembly or final integration steps to mitigate tariff exposure and to maintain supply continuity for critical clinical accounts.

The tariffs also influence commercial dynamics. Payers and procurement officers may push for price concessions or for outcomes-based contracts that shift financial risk. Consequently, manufacturers face a dual imperative: preserve clinical and digital performance while containing delivered costs through design efficiencies, supplier diversification, and operational resilience. Taken together, these measures aim to protect access and competitiveness in a trade environment that has introduced elevated uncertainty.

Segment-specific intelligence revealing how device subtypes, therapeutic classes, care settings, and distribution pathways jointly determine development priorities and commercial strategies

Insights drawn from the segmentation framework reveal differentiated growth drivers and development priorities across device types, drug modalities, end users, and distribution channels. Based on Device Type, the ecosystem encompasses Infusion Pumps, Inhalers, Injection Devices, Nasal Spray, and Transdermal Patch. Within infusion pumps, Enteral Pumps, Insulin Pumps, and PCA Pumps present distinct clinical interfaces and data requirements, forcing developers to tailor connectivity solutions and safety features according to use setting and user proficiency. The inhaler segment includes Dry Powder Inhalers, Metered Dose Inhalers, and Nebulizers, each imposing unique constraints on sensor integration and dose verification technology due to differences in actuation mechanics and aerosol generation.

Injection Devices are studied across Autoinjectors, Pen Injectors, Safety Syringes, and Standard Syringes, where user ergonomics, dose accuracy, and needle safety mechanisms influence the integration of electronics and adherence-tracking capabilities. Nasal Spray formats subdivide into Manual Spray and Nebulized Spray, a distinction that matters for aerosol characterization, device-to-drug compatibility, and real-world administration patterns. Transdermal Patch modalities, including Matrix Patch and Reservoir Patch, demand attention to skin adhesion, reservoir control, and delivery kinetics, which in turn shape sensor placement and complementing analytics.

Based on Drug Type, the analysis differentiates Biologics, Biosimilars, Small Molecule, and Vaccines, acknowledging that biologic therapies often require cold chain considerations, precision dosing, and compatibility with infusion or injection platforms. Based on End User, insights span Ambulatory Care Centers, Clinics, Home Care, and Hospitals, clarifying how user competencies and care workflows inform training, device ruggedness, and remote support needs. Based on Distribution Channel, the study considers Direct Sales, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, highlighting how channel economics and customer touchpoints affect packaging, documentation, and post-sale digital service models. By aligning product architecture and commercial approaches to these intersecting segments, stakeholders can prioritize investments that address the highest-value combinations of device type, drug modality, care setting, and distribution pathway.

Regional strategic imperatives outlining how regulatory regimes, payer expectations, and health system maturity shape adoption and commercialization across global regions

Regional dynamics exert strong influence on regulatory expectations, reimbursement pathways, and adoption patterns for connected drug delivery devices. In the Americas, healthcare systems are characterized by a mix of private and public payers with high emphasis on evidence of outcomes and cost-effectiveness; this environment incentivizes solutions that demonstrate adherence improvement, reduced hospital utilization, and integration with electronic health records. Manufacturers operating in the Americas often prioritize interoperability standards, commercial models that align with payer contracts, and direct partnerships with integrated delivery networks.

In Europe, Middle East & Africa, heterogeneity across regulatory regimes and procurement processes requires nuanced entry strategies. European regulators and health technology assessment bodies focus on clinical and economic value, driving manufacturers to produce robust real-world evidence and to adapt to centralized and decentralized reimbursement landscapes. The Middle East & Africa region presents opportunities for leapfrogging traditional infrastructure through mobile-enabled solutions, but also demands attention to distribution logistics and localized training programs.

Asia-Pacific encompasses a broad spectrum of maturity from advanced digital health infrastructure to rapidly developing healthcare markets. Adoption here is influenced by government initiatives promoting digital health, a growing emphasis on home-based care, and cost-sensitive procurement policies. Manufacturers targeting Asia-Pacific need to balance global standards with local regulatory compliance, optimize supply chains for regional hubs, and collaborate with local partners to tailor user interfaces, languages, and service models to diverse patient populations.

Strategic company behaviors and competitive approaches demonstrating how platform thinking, focused device excellence, and partnership-led value creation are reshaping competitive positioning

Company strategies in the connected drug delivery domain reveal competing approaches to differentiation, including platform-based ecosystems, focused device excellence, and vertical integration with service offerings. Some firms emphasize modular hardware designs paired with developer-friendly software platforms to attract partners and to create extensible ecosystems for third-party applications. This approach seeks to scale adoption by lowering integration barriers and enabling interoperability with hospital IT and remote monitoring vendors. Other companies concentrate on solving a narrow clinical need exceptionally well, investing heavily in human factors engineering, proprietary sensing technologies, and validated clinical workflows to secure preferred provider status.

A third strategic pathway involves closer alignment with pharmaceutical sponsors and specialty pharmacies, offering co-developed combination products or data-enabled adherence programs that support value-based contracting. Across strategies, leading organizations are strengthening capabilities in cybersecurity, regulatory software lifecycle management, and post-market evidence generation. Competitive advantage increasingly depends on the ability to operationalize data into clinical insights and to present clear value propositions to payers and providers. Partnerships, acquisitions, and collaborative R&D remain common mechanisms to accelerate capability acquisition while spreading development risk across technical and regulatory domains.

Action-oriented recommendations for product leaders, commercial teams, and supply chain executives to accelerate adoption and mitigate operational and regulatory risk

Industry leaders should adopt an integrated set of actions to capture value from connected drug delivery devices while managing operational risks. Begin by embedding user-centered design and clinical workflow integration early in development to ensure devices meet real-world needs and minimize training burdens. Parallel to design work, establish modular architectures that permit component substitution and rapid iteration, which reduces the business impact of supply chain disruptions and tariff-related cost volatility. Invest in rigorous cybersecurity practices and a documented software lifecycle process to meet regulatory expectations and to protect patient safety.

Commercially, pursue bundled value propositions that link device performance to measurable health outcomes and align pricing with payer priorities. Cultivate partnerships with digital health vendors, specialty pharmacies, and hospital IT providers to accelerate interoperability and to create integrated service offerings. Operational resilience requires a diversified supplier base, strategic inventory planning, and contingency sourcing for critical electronic components. Finally, commit to real-world evidence programs and stakeholder education to demonstrate clinical utility and to accelerate adoption across home care, ambulatory, and hospital settings. These combined actions will enhance the ability to deliver clinically meaningful, economically viable connected solutions at scale.

A transparent mixed-methods research approach combining stakeholder interviews, technical assessments, and document analysis to validate practical insights and scenarios

The research methodology is grounded in a mixed-methods approach that combines qualitative interviews, technical analyses, and secondary research to produce validated insights. Primary engagement included structured interviews with clinicians, procurement officers, device engineers, regulatory specialists, and payers to capture practical barriers to adoption, technology preferences, and reimbursement considerations. Technical evaluation assessed device architectures, connectivity options, security frameworks, and integration pathways with electronic health records and remote monitoring platforms to identify implementation constraints and opportunities.

Secondary research complemented primary findings through regulatory guidance documents, standards bodies' publications, patent landscape reviews, and company disclosures to triangulate technology maturity and strategic direction. Data validation employed cross-checks between interview themes and documented evidence, while scenario testing explored implications of supply chain shocks, tariff changes, and regulatory shifts. The methodology emphasizes transparency in assumptions, traceable source citations for factual claims, and iterative validation with subject-matter experts to ensure relevance and practical applicability for decision-makers operating across development, regulatory, and commercial functions.

A concise synthesis of strategic conclusions emphasizing the balance of technical innovation, operational resilience, and evidence-driven commercialization for sustained success

The connected drug delivery landscape presents a combination of technological promise and operational complexity that demands deliberate strategy. Advancements in sensor technologies, wireless connectivity, and analytics create pathways to improve adherence, personalize dosing, and demonstrate outcomes, thereby advancing patient-centric care. At the same time, evolving regulatory expectations, supply chain dynamics, and commercial payment models require manufacturers to align product design, evidence generation, and pricing strategies in a coordinated manner to realize sustained adoption.

Success will depend on the ability to integrate human-centered design with robust digital and cybersecurity practices, to engineer resilient supply chains in the face of trade disruptions, and to develop commercial models that clearly link device-enabled data to clinical and economic value. Organizations that balance technical excellence with pragmatic partnerships and evidence-based commercialization will be best positioned to convert innovation into tangible improvements in patient care and system efficiencies. In this context, timely, focused actions on design, sourcing, and stakeholder alignment will determine which players gain durable advantage.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Connected Drug Delivery Devices Market, by Device Type

• 8.1. Infusion Pumps
  • 8.1.1. Enteral Pumps
  • 8.1.2. Insulin Pumps
  • 8.1.3. PCA Pumps
• 8.2. Inhalers
  • 8.2.1. Dry Powder Inhalers
  • 8.2.2. Metered Dose Inhalers
  • 8.2.3. Nebulizers
• 8.3. Injection Devices
  • 8.3.1. Autoinjectors
  • 8.3.2. Pen Injectors
  • 8.3.3. Safety Syringes
  • 8.3.4. Standard Syringes
• 8.4. Nasal Spray
  • 8.4.1. Manual Spray
  • 8.4.2. Nebulized Spray
• 8.5. Transdermal Patch
  • 8.5.1. Matrix Patch
  • 8.5.2. Reservoir Patch

9. Connected Drug Delivery Devices Market, by Drug Type

• 9.1. Biologics
• 9.2. Biosimilars
• 9.3. Small Molecule
• 9.4. Vaccines

10. Connected Drug Delivery Devices Market, by End User

• 10.1. Ambulatory Care Centers
• 10.2. Clinics
• 10.3. Home Care
• 10.4. Hospitals

11. Connected Drug Delivery Devices Market, by Distribution Channel

• 11.1. Online
• 11.2. Offline

12. Connected Drug Delivery Devices Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Connected Drug Delivery Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Connected Drug Delivery Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Connected Drug Delivery Devices Market

16. China Connected Drug Delivery Devices Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. Adherium Limited
• 17.7. AptarGroup, Inc.
• 17.8. Becton, Dickinson, and Company
• 17.9. Cognita Labs LLC
• 17.10. Eli Lilly and Company
• 17.11. F. Hoffmann-La Roche AG
• 17.12. Findair Sp. z o. o.
• 17.13. Gerresheimer AG
• 17.14. Medtronic PLC
• 17.15. Merck KGaA
• 17.16. Molex LLC
• 17.17. Novartis AG
• 17.18. Novo Nordisk A/S
• 17.19. OPKO Health, Inc.
• 17.20. Otsuka America, Inc.
• 17.21. Presspart Verwaltungs-GmbH
• 17.22. ResMed Inc.
• 17.23. SHL Medical AG
• 17.24. Sulzer Ltd.
• 17.25. Teva Pharmaceutical Industries Ltd.
• 17.26. Viatris Inc.
• 17.27. West Pharmaceutical Services, Inc.
• 17.28. Ypsomed Holding
• 17.29. Zimmer Biomet Holdings, Inc.